Get access

Involvement of CD5+CD19+Cell in steroid-dependent nephrotic syndrome treated with B-cell targeting therapy



This article is corrected by:

  1. Errata: Erratum Volume 55, Issue 2, 262, Article first published online: 16 April 2013

Koji Nagatani, MD, Department of Pediatrics, Uwajima City Hospital, 1-1 Goten-machi, Uwajima, Ehime 798-8510, Japan. Email:


We showed in this study the longitudinal changes of the B-cell counts in patients with steroid-dependent nephrotic syndrome (SDNS) treated with cyclophosphamide (CPM) and mycophenolate mofetil (MMF). In our case with SDNS, this combined therapy not only decreased B-cell counts but also increased CD5+CD19+ (CD5+B)/ CD5-CD19+ (CD5-B) cell ratio. Recurrence was not observed when an elevated CD5+B/CD5-B cell ratio was maintained even after the B cells increased. Therefore, this ratio might be more important than the whole B-cell counts. The changes of this ratio could be a good predictor of the clinical course of the patients treated with B-cell targeting therapy.